March 24, 2020 / 1:33 PM / 10 days ago

BRIEF-Kindred Biosciences Announces Positive Results From Pilot Field Efficacy Study Of Its IL-4/IL-13 Sink Molecule Being Developed For The Treatment Of Atopic Dermatitis In Dogs

March 24 (Reuters) - Kindred Biosciences Inc:

* KINDRED BIOSCIENCES ANNOUNCES POSITIVE RESULTS FROM PILOT FIELD EFFICACY STUDY OF ITS IL-4/IL-13 SINK MOLECULE BEING DEVELOPED FOR THE TREATMENT OF ATOPIC DERMATITIS IN DOGS

* KINDRED BIOSCIENCES INC - HIGHER SUCCESS RATE WAS OBSERVED IN KIND-025 GROUP OVER PLACEBO GROUP FROM WEEK 1 THROUGH WEEK 4

* KINDRED BIOSCIENCES - POSITIVE EFFICACY SIGNALS WERE ALSO DETECTED WITH OTHER ENDPOINTS INCLUDING 20MM OR HIGHER REDUCTION FROM BASELINE IN PVAS SCORE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below